Journal of medical Internet research
May 23, 2025
Shu Jing, Zhenwei Dai, Xiaoyang Liu et al.
5 citations
A 6-week web-based mindfulness program, both conventional and neurofeedback-assisted, reduced symptoms of depression, anxiety, and fatigue among 147 nursing students in Beijing, China. The neurofeedback-assisted version produced larger short-term improvements in depression, anxiety, and mindfulness than the conventional version. However, at 1- and 3-month follow-ups, only anxiety symptoms remained significantly different between groups; other benefits were not sustained. The findings suggest that adding neurofeedback to online mindfulness can enhance immediate mental health benefits, but longer interventions may be needed for lasting effects.
Journal of medical Internet research
June 2, 2025
Shu Jing, Zhenwei Dai, Xiaoyang Liu et al.
1 citation
correction
This is a correction notice for a previously published article. It provides no new findings, arguments, or data.
Molecules
June 18, 2026
Mengxuan Dong, Yi Zhang, Manzhu Cao et al.
Psilocybin, a psychedelic drug with reported anxiolytic and antidepressant potential, is rapidly metabolized to its active metabolite psilocin. Behavioral tests in zebrafish exposed to three doses (20, 40, and 80 μM) for 4 hours showed pronounced hyperactivity and disrupted swimming patterns, with significant increases in zone transitions and shuttle frequency. Mass spectrometry imaging revealed that psilocin distributed widely across tissues including eye, brain, heart, liver, and kidney, with marked accumulation in the brain and periportal liver regions. Relative psilocin signal intensity increased dose-dependently, and the dose-dependent increase in both behavioral hyperactivity and brain psilocin levels suggests a consistent relationship with a central site of action. These findings demonstrate the utility of mass spectrometry imaging for studying drug distribution and offer insights into the biological effects and potential risks of psilocybin.
Brain Research Bulletin
October 27, 2025
Shu Wang, Wei Song, Yuanyuan Gao et al.
A single dose of esketamine rapidly improved depressive-like behavior in a mouse model of Parkinson disease. The drug increased expression of GPR109A in the medial prefrontal cortex and reduced levels of pro-inflammatory markers TNF-α, IL-1β, and IL-6. Blocking GPR109A with mepenzolate bromide eliminated these benefits, indicating that GPR109A signaling is necessary for esketamine's antidepressant and anti-inflammatory effects. The findings suggest that esketamine alleviates Parkinson-related depression by suppressing microglial inflammation via GPR109A.